5-t-Butyl-m-tolunitril | 56184-15-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-t-Butyl-m-tolunitril
• 英文别名: 3-Tert-butyl-5-methylbenzonitrile
• CAS: 56184-15-7
• 化学式: C₁₂H₁₅N
• 分子量: 173.258
• InChiKey: FAVPBOMENWEAOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE ORGANOMETALLIC COMPOUND
  申请人：Samsung Electronics Co., Ltd.

  公开号：US20200392173A1

  公开（公告）日：2020-12-17

  Provided are an organometallic compound represented by Formula 1, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound. M 1 (L 11 ) n11 (L 12 ) n12 L 11 in Formula 1 is a ligand represented by Formula 1-1, and other substituents are the same as described in the detailed description of the specification:

  提供的是由化学式1表示的有机金属化合物，包括该有机金属化合物的有机发光器件，以及包括该有机金属化合物的诊断组合物。 M 1 (L 11 ) n11 (L 12 ) n12 <化学式1> 化学式1中的L 11 是由化学式1-1表示的配体，其他取代基与规范的详细描述中描述的相同。
• [EN] HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLES UTILES EN TANT QU'INHIBITEURS DE KINASE RAF
  申请人：BIOGEN IDEC INC

  公开号：WO2010078408A1

  公开（公告）日：2010-07-08

  The present invention provides compounds of formula (I) useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf -mediated diseases.

  本发明提供了一种化合物，其化学式为（I），可用作Raf蛋白激酶的抑制剂。本发明还提供了这些化合物的组合物，以及治疗Raf介导疾病的方法。
• Thiazolyl mglur5 antagonists and methods for their use
  申请人：Cosford Nicholas D.

  公开号：US20090203903A1

  公开（公告）日：2009-08-13

  The identification of a unique series of compounds which possesses special advantages in terms of drug-like properties due to their possessing advantageous properties in terms of potency and/or pharmacokinetic and/or selectivity and/or in vivo receptor occupancy properties. Specifically, the selection of a 1,3-thiazol-2-yl ring member linked by an ethynylene to the 3 position of a pyridyl ring or the 5 position of a pyrimidinyl ring, wherein the ring is substituted with selected substituents, results in a compound having superior drug-like properties. The invention includes pharmaceutically acceptable salt forms of these heterocyclic compounds, in particular chloride salts and trifluoroacetate salts.

  一系列独特化合物的鉴定，由于它们在药物样性方面具有优势特性，包括在效力、药代动力学、选择性和体内受体占有性质方面具有优势特性。具体来说，选择一个由乙炔基连接到吡啶环的3位或嘧啶环的5位的1,3-噻唑-2-基环成员，其中环被选定取代基取代，将导致一种具有优越药物样性的化合物。该发明包括这些杂环化合物的药用盐形式，特别是氯化盐和三氟乙酸盐。
• PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
  申请人：GILEAD CALISTOGA LLC

  公开号：US20140179718A1

  公开（公告）日：2014-06-26

  The present disclosure provides phosphatidylinositol 3-kinase (PI3K) inhibitors of formula (I), or pharmaceutically acceptable salts thereof, in which n, m, R 1 , R 2 , and R 3 are as defined herein. These compounds are useful for treatment of conditions mediated by one or more PI3K isoforms, such as PI3Kδ. The present disclosure further provides pharmaceutical compositions that include a compound of formula (I), or pharmaceutically acceptable salts thereof, and methods of using these compounds and compositions to treat conditions mediated by one or more PI3K isoforms, such as PI3Kδ.

  本披露提供了公式（I）的磷脂酰肌醇3-激酶（PI3K）抑制剂，或其药学上可接受的盐，其中n，m，R1，R2和R3如本文所定义。这些化合物对于治疗由一个或多个PI3K亚型介导的疾病非常有用，如PI3Kδ。本披露进一步提供了包括公式（I）的化合物或其药学上可接受的盐的制药组合物，并使用这些化合物和组合物的方法来治疗由一个或多个PI3K亚型介导的疾病，如PI3Kδ。
• Bipyridyl amines and ethers as modulators of metabotropic glutamate receptor-5
  申请人：Kamenecka M. Theodore

  公开号：US20070027321A1

  公开（公告）日：2007-02-01

  The present invention is directed to novel bipyridyl amine and ether compounds such as those of Formula (I): (I) (where R?1#191, R?2#191, R?3#191, X and Y are as defined herein) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. The invention is also directed to pharmaceutical compositions comprising these compounds. This invention further provides a method of treatment of these disorders and conditions by the administration of an effective amount of these novel bipyridyl amine and/or ether compounds and/or compositions containing these compounds.

  本发明涉及新型的联吡啶胺和醚化合物，例如公式(I)中的化合物：(I) (其中R?1#191，R?2#191，R?3#191，X和Y如本文所定义)，这些化合物是mGluR5调节剂，可用于治疗或预防涉及mGluR5的疾病和病况，包括但不限于精神和情绪障碍，如精神分裂症、焦虑、抑郁、双相障碍和惊恐，以及治疗疼痛、帕金森病、认知功能障碍、癫痫、昼夜节律和睡眠障碍，如倒班工作引起的睡眠障碍和时差反应、药物成瘾、药物滥用、戒断综合征、肥胖症和其他疾病。本发明还涉及包含这些化合物的药物组合物。本发明还提供了通过给予这些新型联吡啶胺和/或醚化合物和/或含有这些化合物的组合物的有效量来治疗这些障碍和病况的方法。